Altimmune names Richard Menziuso as principal accounting officer

Altimmune, Inc. disclosed in an 8-K filing that its Board of Directors appointed Richard Menziuso as the Company's Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.¹ The board took the action on September 24, 2026. Gregory Weaver will remain the Company's Chief Financial Officer.¹

According to the filing, Mr. Menziuso, age 51, has 28 years of finance and accounting experience, including 12 years in public accounting.¹ His most recent role was at Centessa Pharmaceuticals plc, where he served as Vice President, Corporate Controller of Centessa Pharmaceuticals plc, a biopharmaceutical company, from 2021 until its 2026 acquisition by Eli Lilly.¹

Before Centessa, he served as North America Controller and Head of Global Finance Customer Solutions at Thermo Fisher Scientific (NYSE: TMO) from 2019 to 2021 and as Vice President, Accounting and Controller at Axovant Gene Therapies (Nasdaq: formerly AXGT, now SIOX) from 2017 to 2019.¹ Earlier in his career, Mr. Menziuso held finance and accounting roles at LifeCell Corporation, ConvaTec Healthcare, Tyco International, PricewaterhouseCoopers and Bristol-Myers Squibb.¹ He holds a B.B.A. in Public Accounting from Pace University and is a Certified Public Accountant and Chartered Global Management Accountant.¹

The filing states that there are no arrangements or understandings between Mr. Menziuso and any person other than with the Company pursuant to which he was appointed, no family relationship with any director or executive officer, and no direct or indirect material interest in any related transaction requiring disclosure under Item 404(a) of Regulation S-K.¹

The company also said it will enter into an indemnification agreement with Mr. Menziuso in substantially the same form as agreements with other executive officers, listed as Exhibit 10.7 to the Company's 2025 annual report on Form 10-K.¹